You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates
SBC: APOIMMUNE, INC Topic: NIDDKDESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A Portable Device for Accurate Mouse Tail Vein Injection
SBC: Technology Commercialization Partners LLC Topic: ODPROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A portable multi-parametric optical spectroscopy device for key vascular and metabolic endpoints monitoring in small animals
SBC: Zenalux Biomedical, Inc. Topic: ODAltered vascularity and deregulated metabolism are two important cancer hallmarksInterest in therapeutically exploiting these functional endpoints continues to growsince metabolism and vasculature significantly impact a tumor s fateThere is growing demand for systems level technologies that measure tumor metabolism within an intact microenvironment to inform strategies to prevent resistancerecurre ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A practical platform for in-home remote monitoring of cognitive-frailty
SBC: BIOSENSICS LLC Topic: NIAAbstractCognitive frailtythe combined presence of physical frailty and cognitive impairmentis a strong and independent predictor of cognitive declineThe International Association of Gerontology and Geriatrics and the International Academy on Nutrition and Aging have recommended the use of cognitive frailty assessment to track the progression of mild cognitive impairmentMCItowards dementiaAlzheimer ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A ratcheting prosthetic partial finger using advanced rapid manufacturing technology
SBC: POINT DESIGNS, LLC Topic: NICHDThe Point PartialA Ratcheting Prosthetic Partial FingerUsing Advanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop a purely mechanicalratcheting prosthetic partial fingerthe Point Partialwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s proxi ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
ARCHER- An Extremely Fast Medical Radiation Dose Computing Software
SBC: VIRTUAL PHANTOMS INC Topic: NIBIBDESCRIPTION provided by applicant The goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapy The product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computing The project is motivated by the fact that the market is ripe for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A recombinant matrix to improve autologous tissue grafts
SBC: inSoma Bio Inc Topic: 102Abstract The objective of this proposal is to validate a new regenerative tissue matrix which studies to date indicate may be possible of redefining the limits of autologous fat graftingThis objective is motivated by the currently limited surgical options available to themillion patients undergoing reconstructive plastic surgery each year to treat body disfigurement and dysfunctionA core component ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma
SBC: ARISAPH PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A software tool for objective identification of concussion-related vision disorders using a novel eye-tracking device
SBC: Oculogica Inc. Topic: 102ABSTRACT This project will create the first objective measurement toolthe VisBoxfor the vision subtype of concussionVSCThis will enable physicians to identify VSC without an eye care professionalfor referral to a vision specialist for personalized vision therapy recommendationsThe persistence of concussion symptoms beyond several weeks is often a life altering situation for affected individualsand ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease
SBC: ASTROCYTE PHARMACEUTICALS INC. Topic: NIAPROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health